Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

HitGen of Chengdu Forms Drug Discovery Partnership with Boehringer Ingelheim

publication date: Nov 28, 2017

Chengdu's HitGen announced a drug discovery collaboration with Boehringer Ingelheim, using HitGen's DNA-coded library of 90 billion leads. The latest HitGen collaboration will identify novel small molecule leads for "targets of interest to Boehringer Ingelheim," though no further details were provided. All together, HitGen has disclosed eight collaborations with other pharmas in the last two years. Each one is built on a financial structure of upfront payments plus milestones, though no specific financial information is disclosed. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital